title: Antiretroviral reduction: is it time to rethink the unthinkable?
authors.affiliation: aDivision of Infectious Disease, Emory University School of Medicine, Atlanta, Georgia bDivision of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Colasanti
authors.forename: Vincent C
authors.initials: VC
authors.lastname: Marconi
authors.forename: Babafemi
authors.initials: B
authors.lastname: Taiwo
mesh_terms: D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D024882:Drug Resistance, Viral; D004363:Drug Utilization; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents